Testing effectiveness (Phase 2)Study completedNCT01929655What this trial is testingJapanese BAY88-8223 Monotherapy Phase II StudyWho this might be right forProstatic Neoplasms Bayer 49
Not applicableStudy completedNCT03896984What this trial is testingDescriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).Who this might be right forMetastatic Castration-resistant Prostate Cancer (mCRPC) Bayer 346
Not applicableUnknownNCT03786848What this trial is testingPersonalized Mini-PDX for Metastatic CRPCWho this might be right forProstate Cancer Tianjin Medical University Second Hospital 15
Not applicableEnded earlyNCT02491411What this trial is testingDexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and DocetaxelWho this might be right forHormone-Resistant Prostate CancerMetastatic Prostate CarcinomaProstate Adenocarcinoma+1 more Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Testing effectiveness (Phase 2)Study completedNCT02463799What this trial is testingStudy of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCWho this might be right forProstate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Not applicableNo Longer AvailableNCT01834209What this trial is testingAbiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerWho this might be right forProstate Neoplasms Janssen Research & Development, LLC
Large-scale testing (Phase 3)Study completedNCT00861614What this trial is testingStudy of Immunotherapy to Treat Advanced Prostate CancerWho this might be right forProstate Cancer Bristol-Myers Squibb 988
Testing effectiveness (Phase 2)Looking for participantsNCT07189871What this trial is testing177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsWho this might be right forCastration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more Radiopharm Theranostics, Ltd 61
Early research (Phase 1)WithdrawnNCT03110588What this trial is testingPhase I Trial of PACE for Metastatic Prostate CancerWho this might be right forMetastatic Prostate Cancer University of Alabama at Birmingham
Early research (Phase 1)Ended earlyNCT01510288What this trial is testingPhase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate CancerWho this might be right forProstate Cancer Amsterdam UMC, location VUmc 28
Not applicableLooking for participantsNCT06321679What this trial is testingResponse Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the BoneWho this might be right forCastration-resistant Prostate Cancer European Institute of Oncology 40
Testing effectiveness (Phase 2)Ended earlyNCT04157088What this trial is testingStudy to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)Who this might be right forProstatic Cancer, Castration-Resistant Bayer 30
Testing effectiveness (Phase 2)Ended earlyNCT03999515What this trial is testingErdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerWho this might be right forCastration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more University of Washington 3
Testing effectiveness (Phase 2)Looking for participantsNCT04606446What this trial is testingStudy of PF-07248144 in Advanced or Metastatic Solid TumorsWho this might be right forLocally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer Pfizer 320
Early research (Phase 1)Looking for participantsNCT07540572What this trial is testingInvestigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsWho this might be right forER+, HER 2- Breast CancerNon-small Cell Lung Cancer (NSCLC)Castration-resistant Prostate Cancer (CRPC)+1 more IDEAYA Biosciences 160
Testing effectiveness (Phase 2)Study completedNCT02012296What this trial is testingEnzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate CancerWho this might be right forHormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer University of Chicago 88
Not applicableStudy completedNCT06013475What this trial is testingAn Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World SettingsWho this might be right forNon-metastatic Castration-resistant Prostate Cancer Bayer 1,375
Large-scale testing (Phase 3)Active Not RecruitingNCT02257736What this trial is testingAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Who this might be right forProstatic Neoplasms Aragon Pharmaceuticals, Inc. 982
Early research (Phase 1)Study completedNCT01723475What this trial is testingFirst-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate CancerWho this might be right forProstatic Neoplasms Bayer 47
Testing effectiveness (Phase 2)Study completedNCT04060394What this trial is testingDose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCWho this might be right forMetastatic Castration-resistant Prostate Cancer Laekna Limited 49